BR-AG
18.5.2022 10:05:12 CEST | Business Wire | Press release
As regulatory reporting requirements become more complex and regulators become more demanding on the data quality, financial institutions must deal with time-consuming regulatory reporting processes and manage the associated risks. Tapping into this challenge, PwC Belgium, with the support of technology-collaborator BR-AG, developed Regulatory Reporting Insights , powered by BR-AG’s ATOME Matter and ATOME Particles solutions.
“I am excited about the opportunities this improved collaboration with our trusted technology partner BR-AG will bring. This allows financial institutions not only immediate access to an increased level of trust in their regulatory reporting but also to unlock the insights their regulatory reporting contains that was previously only accessible to supervisors.”
Jeroen Bockaert, Partner and Product & Services Leader at PwC Belgium
“It is truly inspiring that our collaboration with PwC has coined into developing this cutting-edge, data-driven tool. As technology experts, we focus on scalability and reusability of data architecture for different purposes and, above all, trust in the solutions we provide. This is indeed a step forward towards a new reporting culture for financial institutions, who now gain such a level of data insight and trust that compliance and risk mitigation become seamless. This is essential for their sustainable growth.”
Michał Piechocki, CEO and co-founder of Business Reporting Advisory Group (BR-AG)
Technology at the heart of the regulatory reporting value chain
Trust in data is the core component of any endeavor within the regulatory reporting sphere and goes beyond compliance. With extremely demanding regulatory reporting requirements at the heart, companies are turning to trusted advisors to streamline their reporting processes and incorporate the most effective and reliable solutions. Bringing together PwC years’ long experience in providing services to financial institutions and BR-AG’s know-how in applying technology to regulatory reporting processes, the end result is a platform to facilitate trust across the reporting value chain and use data insights to their maximum potential.
Different needs, one ecosystem
Understanding the variety of needs across department stakeholders, Regulatory Reporting Insights caters to the data demands of multiple teams managing finance, risk, and regulatory reporting. Powered by BR-AG’s ATOME Matter and ATOME Particles, the platform translates complex reports into visual insights of key regulatory reporting information and adds a layer of comfort to your data quality assurance.
About BR-AG:
Business Reporting- Advisory Group (BR-AG) is a Polish company providing RegTech solutions for financial institutions in Europe and services in utilizing data exchange standards such as XBRL, ISO 20022 and SDMX. By fusing our experience in the regulatory data and technology space, BR-AG developed regulatory data platforms: ATOME Matter and ATOME Particles to foster interoperability, agility, and collaboration in regulatory compliance.
About PwC Belgium:
At PwC, our purpose is to build trust in society and solve important problems. We’re a network of firms in 155 countries with more than 284,000 people who are committed to delivering quality in assurance, advisory and tax services.
Find out more and tell us what matters to you by visiting us at www.pwc.be .
PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please see www.pwc.com/structure for further details.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220515005019/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202615.5.2026 13:38:00 CEST | Press release
All economic and financial indicators grew:Consolidated revenues of €645.0 million (€607.5 million in 2025);EBITDA of €112.0 million (€105.3 million in 2025);EBIT of €95.1 million (€88.7 million in 2025);Profit before tax amounts to €99.8 million (€86.9 million in 2025). Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover. EBIT, from January to March, was €95.1 million (€88.7 million in 2025) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €99.8 million (€86.9 million in 2025), equal to 15.5% of the turnover. The net financial position of
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release
New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom